NORTHLAND

NORTHLAND

Language

The interim investigator meeting for the Phase IIb clinical study of Project NL005 was successfully held.

发布时间：2022-12-23

On December 22, 2022, the interim investigator meeting for the Phase IIb clinical study of Recombinant Human Thymosin β4 Injection (NL005), hosted by NORTHLAND and led by Professor Dou Kefei from Fuwai Hospital, Chinese Academy of Medical Sciences, was successfully held. More than 30 investigators from 14 hospitals across the country, along with project leaders and members from the sponsor, CRO, and SMO companies, gathered virtually to attend the meeting.

07

2022-11

NORTHLAND Selected as a Constituent Stock of the North Exchange 50 Index

发布时间：2022-11-07

On November 4, 2022, the Beijing Stock Exchange released the list of constituent stocks for the BSE 50 Index (hereinafter referred to as the “BSE 50”). Our company was selected as a constituent stock and ranks among the top five largest-weighted stocks.

23

2022-10

The paper detailing the rationale and design of the Phase III clinical trial (HOPE CLTI) for NL003 in the treatment of severe limb ischemia has been published in the *American Heart Journal*.

发布时间：2022-10-23

Recently, a paper detailing the rationale and design of the Phase III clinical trial for our company’s gene therapy drug, “Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection” (NL003), which is used to treat critical limb ischemia (CLTI), was published in the American Heart Journal. The journal’s 2021 impact factor was 5.099.

27

2022-09

The long-term follow-up observation of subjects in the Phase II clinical trial of NL003 has officially commenced.

发布时间：2022-09-27

Recently, the “Long-term Follow-up Study of Subjects in the NL003 Phase II Clinical Trial,” initiated by the team led by Professor Gu Yongquan from the Department of Vascular Surgery at Xuanwu Hospital, has been approved and officially entered the launch phase at Xuanwu Hospital of Capital Medical University. This project is conducted as a investigator-initiated trial, with the participation of nine research centers that took part in the Phase II clinical trial. The study is scheduled to be completed by December 2022.

16

2022-08

In partnership with IQVIA, we are launching a study on the commercialization strategy for the NL003 project.

发布时间：2022-08-16

Recently, our company officially signed a commercialization consulting agreement with IQVIA Management Consulting (Shanghai) Co., Ltd. (hereinafter referred to as “IQVIA”) for the recombinant human hepatocyte growth factor naked plasmid injection (code-named NL003). Guided by the principles of complementary strengths and mutual development, the two parties will engage in in-depth collaboration on the research of commercialization strategies for the NL003 project.

18

2022-07

The first patient has been enrolled in the Phase IIb clinical trial for NL005.

发布时间：2022-07-18

On July 15, 2022, our company’s Phase IIb clinical trial of “Recombinant Human Thymosin β4 for Injection” (code name NL005) for the treatment of ischemia-reperfusion injury in acute myocardial infarction successfully enrolled its first patient at the leading center, Fuwai Hospital of the Chinese Academy of Medical Sciences. On July 16, another patient was successfully enrolled, marking the start of an accelerated pace for the clinical trial.

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Friendly Links: Baidu | NORTHLAND

NORTHLAND

Contact Information

Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing

Hotline: +86 010-82890893

Email: northland@northland-bio.com

Website: www.northland-bio.com

Complaints Reporting Hotline: +86 010-82890893-8031

Complaints Reporting Email: pv@northland-bio.com

Follow Us

Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.

WeChat Mini Program

Web site

WeChat Official Account

NL-BIO

Scientific Research on Lower Limb Ischemia

NL003

Myocardial Infarction Scientific Research

NL005

Business license

Powered by 300.cn  Privacy Policy